Nurix Therapeutics (NASDAQ:NRIX) Given New $35.00 Price Target at HC Wainwright

Nurix Therapeutics (NASDAQ:NRIX - Free Report) had its price objective lifted by HC Wainwright from $30.00 to $35.00 in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research analysts also recently commented on the stock. Royal Bank of Canada decreased their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating for the company in a research report on Monday, October 14th. Stephens reiterated an "overweight" rating and set a $31.00 target price on shares of Nurix Therapeutics in a research note on Monday, October 14th. BTIG Research began coverage on Nurix Therapeutics in a report on Tuesday. They set a "buy" rating and a $35.00 price target for the company. BMO Capital Markets assumed coverage on shares of Nurix Therapeutics in a research report on Friday, December 6th. They issued an "outperform" rating and a $35.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 target price on shares of Nurix Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $30.35.

Nurix Therapeutics Stock Down 3.4 %

Shares of NRIX traded down $0.75 on Wednesday, hitting $21.31. The company's stock had a trading volume of 749,755 shares, compared to its average volume of 904,775. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -7.58 and a beta of 2.11. The firm's fifty day moving average price is $23.72 and its 200-day moving average price is $22.10. Nurix Therapeutics has a fifty-two week low of $7.65 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.67). The firm had revenue of $12.59 million during the quarter, compared to analysts' expectations of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, equities analysts predict that Nurix Therapeutics will post -2.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 3,546 shares of the company's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the sale, the chief financial officer now owns 33,724 shares of the company's stock, valued at approximately $818,818.72. This represents a 9.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christine Ring sold 3,290 shares of the business's stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $25.00, for a total value of $82,250.00. Following the completion of the sale, the insider now owns 24,592 shares of the company's stock, valued at $614,800. The trade was a 11.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,401 shares of company stock valued at $437,453 in the last quarter. Corporate insiders own 7.20% of the company's stock.

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NRIX. Amalgamated Bank increased its position in Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company's stock worth $49,000 after buying an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock valued at $54,000 after acquiring an additional 559 shares in the last quarter. Quarry LP boosted its stake in shares of Nurix Therapeutics by 3,746.2% in the third quarter. Quarry LP now owns 2,500 shares of the company's stock worth $56,000 after acquiring an additional 2,435 shares during the period. International Assets Investment Management LLC raised its stake in Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company's stock valued at $101,000 after purchasing an additional 4,119 shares during the period. Finally, Quest Partners LLC lifted its holdings in Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after purchasing an additional 1,312 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.